We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Oncolytics Biotech REOLYSIN® Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study

News   Dec 15, 2008

 
Oncolytics Biotech REOLYSIN® Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study
 
 
 

RELATED ARTICLES

Aspirin Stops Clots After Knee Surgery

News

Putting patients on aspirin following a knee replacement is a safe, cost-effective alternative to anticoagulants, U-M researchers find.

READ MORE

Treating the Prostate with Radiotherapy Improves Survival

News

Treating the prostate with radiotherapy alongside standard treatment led to a 11 percent increase in survival for some men with advanced prostate cancer, shows trial.

READ MORE

5.1 Million Dollar Funding Boost for Blinding Retinal Conditions

News

A $5.1 million grant has been awarded from the California Institute for Regenerative Medicine to advance the development of a novel therapy for blinding retinal conditions.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE